Connect your AI

Organon OGN Payments to Acquire in Process Research and Development

Payments to Acquire in Process Research and Development at other companies

BiogenBIIB

——

Other financials

Income statement

Revenue$1.5B-3.5%

Gross profit$783.0M-6.9%

Net income$146.0M+67.8%

EPS (diluted)$0.55+66.7%

Balance sheet

Cash & equivalents$1.1B+104%

Total debt$8.6B-4.3%

Total equity$903.0M+66.6%

Total assets$13.0B-1.2%

Cash flow

Operating cash flow$225.0M+200%

CapEx$37.0M+15.6%

Free cash flow$188.0M+337%

Valuation

Market cap$3.53B-59.4%

Profitability

Gross margin52.8%-4.4pp

Net margin8%-12.3pp

FCF margin11.1%-1.3pp

Returns & leverage

Return on equity71.6%—

Debt / equity9.5×-7.0×

Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's payments to acquire in process research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Organon's payments to acquire in process research and development?: Organon (OGN) reported payments to acquire in process research and development of $10M in Q1 2026.
How has Organon's payments to acquire in process research and development changed year-over-year?: Organon's payments to acquire in process research and development decreased by 0.0% year-over-year, from $10M to $10M.